NCT05297994View on ClinicalTrials.gov

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

October 24, 2016

Primary Completion Date

December 12, 2016

Study Completion Date

March 9, 2017

Conditions
Influenza
Interventions
BIOLOGICAL

Flu-M [Inactivated split influenza vaccine]

solution for intramuscular injection, 0.5 ml

BIOLOGICAL

Inactivated influenza split vaccine

solution for intramuscular injection, 0.5 ml

Trial Locations (3)

Unknown

Infection Center, Novosibirsk

Perm State Medical University named after Academician E. A. Wagner, Perm

Research Institute of Influenza, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg Research Institute of Vaccines and Sera

OTHER_GOV

NCT05297994 - Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA | Biotech Hunter | Biotech Hunter